Cover Image
市場調查報告書

類風濕性關節炎 (RA) - 市場預測

Rheumatoid Arthritis (RA) - Dynamic Market Forecast to 2025

出版商 GlobalData 商品編碼 611767
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
類風濕性關節炎 (RA) - 市場預測 Rheumatoid Arthritis (RA) - Dynamic Market Forecast to 2025
出版日期: 2017年11月30日 內容資訊: 英文 51 Pages
簡介

本報告提供類風濕性關節炎(RA)市場調查,市場上3大活動及相關的治療藥的最新資訊,各治療藥的市場佔有率及銷售額的變化與預測,醫生的市場未來展望等相關彙整。

第1章 市場預測

  • 相關調查
  • 出版預定的相關報告

第2章 摘要整理

  • 主要的更新資訊
  • 臨床試驗的最新資訊
  • 開發平台相關最新資訊
  • 市場考察

第3章 活動1:大幅度轉移到生物相似藥

  • 生物相似藥市場預測
  • Enbrel的生物相似藥
  • Humira的生物相似藥
  • Remicade的生物相似藥
  • Rituxa的生物相似藥
  • 醫生的見解
  • 資訊來源

第4章 活動2:Sirukumab的開發中止伴隨的抗IL-6單株抗體製劑的新市場機會

  • 坑IL-6單株抗體製劑市場最新資訊
  • Sirukumab:Jonson & Johnson
  • Sarilumab:Regeneron,Sanofi
  • 醫生的見解
  • 市場趨勢和總論

第5章 活動3:JAK抑制劑的競爭

  • JAK抑制劑市場最新資訊
  • Olumiant(Baricitinib):Eli Lilly
  • Upadacitinib:AbbVie
  • 醫生的見解
  • 市場趨勢和總論
  • 資訊來源

第6章 活動日曆

第7章 附錄

目錄
Product Code: GDHC003FS

Rheumatoid Arthritis (RA) is a rapidly evolving field in which new developments are constantly influencing the market landscape. The Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the RA space, including regulatory, commercial, and clinical events as well as understand how all of these events will impact the projected market forecast.

Scope

Key events covered in the Dynamic Market Forecast include -

  • Regulatory filings
  • Approval decisions
  • Pricing changes
  • Patent litigation
  • Clinical trial data announcements
  • Clinical trial failures
  • Clinical trial timeline updates

Components of the slide deck include -

  • Timeline of market-impacting events
  • Key clinical trial landscape updates
  • Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective
  • Overview of updates to the forecast model based on anticipated future impact of events
  • Forward-looking events calendar listing expected key updates to the RA competitive space through June 2018

Reasons to buy

  • Recent Regulatory Events
  • Recent Commercial Events
  • Recent Clinical Events
  • Market Dynamics Shifts Towards Biosimilars in the RA Setting
  • Discontinuation of J&J's Sirukumab for RA Creates Opportunity for Other IL-6 Inhibitors
  • Increased Competition Among the Oral JAK Inhibitors in the RA Setting

Table of Contents

  • 1. Dynamic Market Forecast Overview 5
  • 1.1 Related Reports 6
  • 1.2 Upcoming Related Reports 7
  • 2. Executive Summary 8
  • 2.1 Key Updates to RA Market Dynamics 9
  • 2.1 Key Events in Update 10-12
  • 2.2 Clinical Trial Landscape Updates 13
  • 2.3 Pipeline Landscape Updates 14
  • 2.4 Market Insight on Key Events 15
  • 3. Event 1: Market Dynamics Shift Towards Biosimilars 16
  • 3.1 Key Updates to Biosimilar Market Dynamics 17
  • 3.2 Enbrel Biosimilars 18
  • 3.3 Humira Biosimilars 19
  • 3.4 Remicade Biosimilars 20
  • 3.5 Rituxan Biosimilars 21
  • 3.6 What Do Physicians Think? 22
  • 3.7 Summary/Trends 23
  • 3.8 Sources 24
  • 4. Event 2: Discontinuation of Sirukumab Creates Opportunity for Other IL-6 Inhibitors 25
  • 4.1 Key Updates to the Anti-IL-6 Market Dynamics 26
  • 4.2 J&J, sirukumab 27
  • 4.3 Regeneron/Sanofi, Kevzara (sarilumab) 28
  • 4.4 What Do Physicians Think? 29
  • 4.5 Summary/Trends 30
  • 4.6 Sources 31
  • 5. Event 3: Competition Among the Oral JAK Inhibitors 32
  • 5.1 Key Updates to the JAK Inhibitor Market Dynamics 33
  • 5.2 Eli Lilly, Olumiant (baricitinib) 34-35
  • 5.3 AbbVie, upadacitinib 36
  • 5.4 What Do Physicians Think? 37
  • 5.5 Summary/Trends 38
  • 5.6 Sources 39
  • 6. Events Calendar 40
  • 6.1 Key Events Expected to Occur H1 2018 41
  • 7. Appendix 42
  • 7.1 Methodology 43
  • 7.2 Primary Research 44-45
  • 7.3 About the Authors 46-48
  • 7.4 About GlobalData 49
  • 7.5 Contact Us 50
  • 7.6 Disclaimer 51
Back to Top